Aurora Cannabis (TSE:ACB) PT Set at C$10.00 by Canaccord Genuity Group

Aurora Cannabis (TSE:ACB) has been given a C$10.00 target price by Canaccord Genuity Group in a research note issued to investors on Tuesday, MarketBeat Ratings reports. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity Group’s price target would suggest a potential upside of 70.65% from the company’s current price.

Separately, ATB Capital dropped their price target on shares of Aurora Cannabis from C$9.00 to C$8.50 and set an “outperform” rating on the stock in a research report on Thursday, December 11th. One equities research analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of C$9.25.

Aurora Cannabis Stock Down 2.7%

ACB opened at C$5.86 on Tuesday. The stock’s 50 day moving average price is C$6.23 and its 200 day moving average price is C$6.68. The company has a debt-to-equity ratio of 18.72, a current ratio of 3.42 and a quick ratio of 2.48. The stock has a market cap of C$329.60 million, a P/E ratio of -5.75 and a beta of 0.71. Aurora Cannabis has a 12 month low of C$4.95 and a 12 month high of C$9.90.

Aurora Cannabis (TSE:ACB) last released its quarterly earnings results on Wednesday, November 5th. The company reported C($0.91) earnings per share (EPS) for the quarter. Aurora Cannabis had a negative return on equity of 8.36% and a negative net margin of 22.55%.The business had revenue of C$90.37 million during the quarter. As a group, research analysts predict that Aurora Cannabis will post -0.22 earnings per share for the current year.

Aurora Cannabis Company Profile

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael ’71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.